DLA 001
Alternative Names: DLA - Dualogics; DLA-001Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Dualogics
- Class Bispecific antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Type 1 diabetes mellitus
- No development reported Graft-versus-host disease; Irritable bowel syndrome; Multiple sclerosis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Graft-versus-host-disease in USA (Parenteral)
- 28 Sep 2024 No recent reports of development identified for research development in Irritable-bowel-syndrome in USA (Parenteral)
- 28 Sep 2024 No recent reports of development identified for research development in Multiple-sclerosis in USA (Parenteral)